SANA - Sana Biotechnology cools after record-breaking rally
2024-01-11 10:49:59 ET
Sana Biotechnology ( NASDAQ: SANA ) dropped ~10% in the morning hours Thursday as the cell therapy developer pared gains from a 52-week high it reached yesterday following its presentation at the J.P. Morgan Healthcare Conference.
About ~3.6M SANA shares have changed hands so far compared to the 65-day average of ~2.6M as the stock continues to trade over 80% below its IPO price in February 2021.
Seeking Alpha contributor Stephen Ayers upgraded SANA to Hold from Sell on Thursday, citing the management’s financial discipline and progress in R&D.
However, he points to the stock’s high short interest. The Seattle, Washington-based biotech backed by Flagship Pioneering, the venture capital firm behind Moderna ( MRNA ), has almost 20% short interest.
With more than 21M of its shares on loan and a days-to-cover ratio of ~13.4, this “high interest points to market doubts,” the analyst wrote.
More on Sana Biotechnology
- Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)
- Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
- Sana Biotechnology: Still Early Days, Lots Of Dilution Ahead
- Sana Biotechnology hits 52-week high amid rising volumes
- Sana gets FDA clearance to initiate clinical study for SC262
For further details see:
Sana Biotechnology cools after record-breaking rally